Patent No. US9333371 (titled "Variable intensity laser treatments of the skin") on Oct 29, 2013. The application was issued on May 10, 2016.
’371 is related to the field of non-ablative dermatological laser treatments. Specifically, it addresses the challenge of heating the dermal layers of the skin to a therapeutic level—sufficient to trigger collagen remodeling and heat-shock protein release—without exceeding the pain threshold or causing epidermal damage. The invention provides a mechanism for achieving a precise thermal plateau rather than a simple peak-and-decay profile.
The underlying idea behind ’371 is that the most effective way to stimulate skin rejuvenation without pain is to rapidly reach a target temperature window and then hold it there using a non-linear energy delivery strategy. By dynamically adjusting the optical fluence during a single, short treatment cycle, the system can overcome the natural thermal diffusion of tissue. This prevents the common problem where a constant stream of energy either takes too long to reach therapeutic levels or overshoots into temperatures that cause burning and discomfort.
The claims of ’371 focus on a handheld, self-contained laser system that utilizes specific wavelengths between 1380 nm and 1570 nm to target depths of 100 to 800 microns. The independent claims specifically protect the method of varying pulsed beam parameters—such as intensity, pulse width, or inter-pulse delay—within a brief 0.2 to 1.5 second window. This modulation is designed to maintain a dermal temperature strictly between 39 and 45 degrees Celsius while delivering a total energy density of 1.5 to 5.0 Joules per square centimeter.
In practice, the invention operates by delivering energy in distinct stages. An initial high-energy burst quickly drives the tissue to the desired temperature. The controller then shifts to a lower-energy phase to allow for thermal diffusion and prevent overshooting the pain threshold, followed by a maintenance phase that provides just enough energy to keep the temperature stable. This is achieved by shortening pulse widths, increasing the time between pulses, or stepping down the laser current as the treatment progresses.
This approach differs from prior solutions that typically use uniform pulse trains, which result in a linear temperature rise followed by a rapid drop-off. By employing a multi-group pulse strategy, the invention maximizes the time the tissue spends in the therapeutic zone. Furthermore, the integration of safety sensors ensures that the laser only fires when in full contact with the skin, preventing light leakage and ensuring the energy is delivered precisely to the targeted dermal locus.
In the early 2010s when ’371 was filed, dermatological energy delivery systems were typically implemented using static control interfaces where operational parameters were manually fixed prior to the initiation of a procedure. At a time when systems commonly relied on pre-set values for optical power, pulse width, and frequency to deliver a consistent energy stream, hardware and software constraints made the real-time modulation of energy delivery based on dynamic feedback or variable treatment cycles non-trivial. Consequently, standard engineering practices focused on maintaining high-intensity output through fixed current settings for laser diodes or light-emitting diodes, rather than adaptive control architectures.
The disclosed invention represents a technical advancement by transitioning from static energy delivery to a more granular control architecture that manages the interplay between optical power, pulse duration, and duty cycles. This architectural shift addresses the technical problem of localized tissue damage by enabling precise manipulation of energy intensity and thermal relaxation intervals through interchangeable control variables. The integration of these parameters allows for a more sophisticated treatment cycle that can be optimized for specific dermal responses, overcoming the limitations of traditional systems that were restricted to uniform pulse sequences.
The patent contains a total of 14 claims, with claims 1, 12, and 14 serving as the independent claims. These independent claims focus on a handheld, self-contained laser system and associated methods for localized skin treatment that utilize specific wavelengths and pulsed beam parameters to maintain target tissue temperatures between 39 and 45 degrees Celsius. The dependent claims serve to further define the operational characteristics of the system, including specific pulse grouping sequences, variations in pulse width and intervals, safety sensor integration, and data communication capabilities for software updates and charging.
Definitions of key terms used in the patent claims.
US Latest litigation cases involving this patent.

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Get instant alerts for new documents